Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity.
Curr Opin Investig Drugs. 2006 Oct;7(10):924-35.
Abstract: Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed.